Free Trial

Dianthus Therapeutics (DNTH) Competitors

Dianthus Therapeutics logo
$35.65 -0.35 (-0.97%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$35.66 +0.01 (+0.01%)
As of 10/17/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DNTH vs. KYMR, PTGX, CRNX, ZLAB, AKRO, ACAD, AAPG, MIRM, LNTH, and MENS

Should you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry.

Dianthus Therapeutics vs. Its Competitors

Kymera Therapeutics (NASDAQ:KYMR) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Dianthus Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$44.71M95.68-$223.86M-$3.47-17.24
Dianthus Therapeutics$4.85M236.40-$84.97M-$3.25-10.97

47.5% of Dianthus Therapeutics shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 8.2% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Kymera Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.

In the previous week, Kymera Therapeutics had 2 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 11 mentions for Kymera Therapeutics and 9 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.75 beat Kymera Therapeutics' score of 0.16 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
5 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Dianthus Therapeutics
2 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kymera Therapeutics presently has a consensus target price of $62.74, indicating a potential upside of 4.86%. Dianthus Therapeutics has a consensus target price of $60.88, indicating a potential upside of 70.76%. Given Dianthus Therapeutics' higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
1 Sell rating(s)
1 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.95
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Kymera Therapeutics has a net margin of -616.03% compared to Dianthus Therapeutics' net margin of -2,364.56%. Kymera Therapeutics' return on equity of -31.60% beat Dianthus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-616.03% -31.60% -27.12%
Dianthus Therapeutics -2,364.56%-34.72%-32.72%

Summary

Kymera Therapeutics beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Dianthus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DNTH vs. The Competition

MetricDianthus TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.15B$3.43B$6.20B$10.53B
Dividend YieldN/A2.28%5.70%4.82%
P/E Ratio-10.9723.1685.7027.13
Price / Sales236.40457.02583.17177.90
Price / CashN/A46.9237.1060.81
Price / Book2.9910.4112.236.52
Net Income-$84.97M-$52.77M$3.33B$276.93M
7 Day Performance3.45%2.31%1.17%1.93%
1 Month Performance-2.99%12.59%6.85%2.19%
1 Year Performance22.72%11.18%58.93%34.62%

Dianthus Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DNTH
Dianthus Therapeutics
2.7006 of 5 stars
$35.65
-1.0%
$60.88
+70.8%
+22.7%$1.15B$4.85M-10.9780News Coverage
Analyst Forecast
KYMR
Kymera Therapeutics
1.011 of 5 stars
$57.55
-0.6%
$61.26
+6.5%
+28.9%$4.14B$47.07M-16.58170Analyst Forecast
Insider Trade
PTGX
Protagonist Therapeutics
1.9405 of 5 stars
$64.14
-1.1%
$68.36
+6.6%
+65.0%$4.03B$209.18M91.63120Analyst Forecast
Insider Trade
CRNX
Crinetics Pharmaceuticals
4.3718 of 5 stars
$41.68
+2.0%
$74.45
+78.6%
-29.6%$3.93B$1.39M-10.14210Positive News
ZLAB
Zai Lab
2.7583 of 5 stars
$33.31
-1.3%
$56.35
+69.2%
+2.9%$3.77B$398.99M-16.331,869News Coverage
Gap Up
AKRO
Akero Therapeutics
3.5508 of 5 stars
$46.04
-0.1%
$81.14
+76.2%
+72.4%$3.69BN/A-23.0230Insider Trade
ACAD
ACADIA Pharmaceuticals
3.9358 of 5 stars
$21.59
-1.0%
$29.12
+34.9%
+36.5%$3.68B$1.02B16.23510Analyst Forecast
Gap Up
AAPG
Ascentage Pharma Group International
N/A$39.86
+1.2%
N/AN/A$3.67B$134.35M0.00600
MIRM
Mirum Pharmaceuticals
3.5889 of 5 stars
$72.53
-0.6%
$76.50
+5.5%
+86.3%$3.66B$336.89M-59.94140Trending News
Analyst Forecast
Analyst Revision
LNTH
Lantheus
4.5269 of 5 stars
$52.70
-2.1%
$85.50
+62.2%
-52.4%$3.66B$1.53B14.02700Trending News
Analyst Revision
MENS
Jyong Biotech
N/A$52.01
+8.4%
N/AN/A$3.65BN/A0.0031Positive News

Related Companies and Tools


This page (NASDAQ:DNTH) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners